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Abstract
With recent advances in cardiac imaging, genetics, and treatment options, cardiac amyloidosis (CA) is now recognized as
an important and under diagnosed condition contributing to cardiovascular morbidity and mortality. Although still considered a rare disease, CA is now recognized as an important contributor to heart failure with preserved ejection fraction
(HFPEF) and low gradient aortic stenosis, two important conditions commonly faced in clinical practice. This review uses
clinical scenarios to highlight the complementary role of traditional imaging tools such as electrocardiogram (ECG) and
echocardiography (echo) in conjunction with advanced cardiac imaging with cardiac magnetic resonance (CMR) and nuclear
cardiac scintigraphy using bone avid tracers in the comprehensive workup of CA. We also highlight the importance of workup
of light chain disease as part of integration of imaging findings and discuss the key aspects of various imaging modalities.
Finally, an algorithm integrating clinical suspicion, laboratory testing, and imaging in the workup of CA is presented.
Keywords Cardiac amyloidosis · Light chain cardiac amyloidosis · Transthyretin cardiac amyloidosis · Electrocardiogram ·
Echocardiogram · Cardiac magnetic resonance · Technetium-99 m pyrophosphate · Multimodality imaging

Introduction
Cardiac amyloidosis (CA) is a rare restrictive infiltrative
cardiomyopathy characterized by extracellular amyloid
fibril infiltration leading to thickening of ventricular walls,
increased ventricular stiffness, and consequently high
ventricular filling pressures. Various forms of CA have
been identified, with AL-cardiac amyloidosis (AL-CA)
and transthyretin cardiac amyloidosis (ATTR-CA) being
the most clinically relevant. Evaluation of CA requires
heightened suspicion of CA's unique clinical manifestations in addition to understanding the electrocardiography
(EKG), echocardiographic (echo), and radionuclide as well
as cardiac magnetic resonance (CMR) imaging nuances.
Apart from imaging, cardiac biomarkers, genetic analysis,
and histopathological confirmation with tissue sampling
play a key role for solidifying the diagnosis as well as for
staging and management. For the purposes of this manuscript, cardiac nuclear scintigraphy will primarily focus on
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Technetium-99m pyrophosphate imaging (PYP) as other
bone avid tracers are not available for clinical use in the
USA.

AL‑CA vs ATTR‑CA
Morbidity and mortality related to CA is significant if
diagnosis is delayed. This is partially due to large lag time
between suspicion and diagnosis and in many cases misdiagnosis. Untreated, the median survival from onset of AL amyloidosis to congestive heart failure (CHF) is approximately
6 months [1], but modern therapies have extended that to
5 years, with increasing survival beyond 10 years [2]. The
median survival of ATTR-CA is about 3–5 years in untreated
individuals [3]. The ATTR staging system from the U.K.
National Amyloidosis Center which included both wild type
(wt-ATTR-CM) and hereditary (mtATTR) used N-terminal
pro–B-type natriuretic peptide threshold of > 3,000 pg/ml)
and estimated glomerular filtration rate (< 45 ml/min/1.73
m2) and reported a median survival for stage II wtATTR
patients of 49 months and a survival of 29 months in patients
with mtATTR (Val122Ile mutation only) [4]. Clinical observations have suggested that the severity of heart failure in
AL-CA is more severe than in ATTR-CA, despite higher left
ventricular (LV) mass in ATTR [5]. This is likely related to
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Fig. 1  A relatively benign appearing ECG in a patient with wtATTR-CA with normal precordial voltage

direct light chain toxicity and non-inflammatory edema in
addition to interstitial infiltration [6].
This section discusses the integral role of multimodality
imaging in the diagnosis of CA by illustrating 3 clinical scenarios of patients diagnosed with CA in our Amyloid Clinic
with multimodality imaging. Each case illustrates a teaching
point. The cases are used to discuss key aspects of various
imaging modalities and how they are integrated towards
diagnosis of CA. We summarize by providing a diagnostic
algorithm our institution uses in the workup of CA.

Case 1: Role of multimodality imaging
in clarifying etiology of hypertrophied
ventricle
Seventy-seven-year-old male initially diagnosed as hypertrophic cardiomyopathy (HCM) based on CMR and echo
with history of atrial fibrillation on Eliquis. Serial echo
during follow-up showed new left ventricular dysfunction
prompting repeat cardiac MRI which showed abnormal diffuse gadolinium enhancement of the myocardium more suggestive of an infiltrative process like amyloidosis. Parametric
mapping techniques were not available at our institution at
time of this MRI. Monoclonal protein screen and serum
urine electrophoresis/immunofixation were negative for light
chain disease. Endomyocardial biopsy (EMB) was attempted
given the conflicting prior diagnosis of HCM, but the patient
developed transient complete heart block and biopsy was
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aborted. He subsequently underwent an abdominal fat pad
biopsy, which was reported as negative. Ultimately, a PYP
scan was done with strongly positive myocardial uptake with
H/CL ratio of 2.4 and grade 3 visual uptake with diffuse
myocardial uptake on SPECT which helped confirm diagnosis of ATTR-CA. TTR DNA sequencing was negative for
mutations. Therefore, a diagnosis of wtATTR was made.
The patient is currently on Tafamidis.

Teaching point
CA should be considered in the differential of hypertrophied
ventricles. Specifically, CA should be considered when a
new diagnosis of hypertrophic cardiomyopathy is considered
in the middle to older age patient.

Patient 2: Multimodality imaging in a patient
with elevated light chains
Seventy-six-year-old male with CAD with prior percutaneous interventions, peripheral arterial disease, and atrial
fibrillation with prior normal ejection fraction (EF) of 55%
presents with new decline in EF to 40%. Patient relevant
past history included bilateral carpel tunnel syndrome,
lumbar spinal stenosis, and rotator cuff tear apart from
other medical co-morbidities. CMR was ordered showing
diffuse increased LV wall thickness, diffuse myocardial
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Fig. 2  ECG in patient 1 with wtATTR-CA showing left bundle branch block and voltage criteria for left ventricular hypertrophy. Another example of absence of low voltage in ATTR

delayed enhancement along with elevated native T1 relaxation times, and markedly increased myocardial extracellular volume all suggestive of CA. Workup for light chain
disease was abnormal. He underwent hematological evaluation as well as bone marrow biopsy. Congo red stain was
positive for amyloid deposits. Liquid chromatography tandem mass spectrometry was performed on the Congo red
positive microdissected areas of paraffin embedded specimens (Mayo Clinic laboratories) and a peptide sequence
consistent with ATTR amyloid protein deposition was
noted. Subsequent amino acid sequencing was negative
for mtATTR and hence a final diagnosis of wtATTR was
established. PYP scintigraphy showed a H/CL ratio of 1.6
and grade 3 visual uptake with diffuse myocardial uptake
on SPECT. Salivary genetics was negative for mtATTR.
A multidisciplinary review of the case with hematology
and cardiology was done. Based on above findings, an
endomyocardial biopsy was deemed not necessary. A final
diagnosis of wtATTR with coexistent monoclonal gammopathy of unknown significance (MGUS) was made.
The patient is currently on Tafamidis. His most recent
office visit 6 months post Tafamidis showed primarily
progression of cervical spinal canal narrowing needing

neurosurgical intervention with stable cardiac status and
no active cardiac symptoms.

Teaching point
Comprehensive workup is needed to evaluate light chain
disease prior to diagnosing ATTR-CA. MGUS can coexist
with ATTR-CA.

Patient 3: Multimodality imaging
in diagnosis of hereditary amyloid
neuropathy with mixed phenotype
including cardiomyopathy
Fifty-year-old male with bilateral carpal tunnel, syncope,
severe orthostatic hypotension, PVCs, chronic diarrhea, and
bilateral leg numbness requiring a cane for walking was
evaluated for CA. Echo indicated thickened LV walls, which
raised suspicion for HCM versus amyloidosis. Cardiac MRI
with gadolinium showed diffuse LGE more consistent with
CA. Serum urine immunofixation and monoclonal protein

13

Heart Failure Reviews

Fig. 3  ECG in mtATTR (patient 3). Pseudo-infarct pattern is present. Patient has no history of CAD. Again, note the relatively preserved precordial voltage

screen were negative for light chain disease. Fat pad biopsy
was positive for Congo red positive amyloid fibrils and confirmed with mass spectroscopy to be ATTR. PYP scintigraphy was also consistent with ATTR cardiac amyloidosis
with H/CL ratio 1.9 and diffuse myocardial SPECT uptake.
Salivary genetic analysis was positive for T60A mutation.
Neurological evaluation and workup confirmed Familial
Amyloid Polyneuropathy (FAP) with severe disabling autonomic symptoms in addition to ATTR-CA. He was initiated on midodrine and patisiran for FAP given disabling
neurological symptoms. Given concomitant cardiac involvement, he is also currently under evaluation for addition of
Tafamidis.

The case for non‑biopsy diagnosis
of amyloidosis with multimodality imaging
The gold standard for diagnosis of cardiac amyloidosis
remains EMB from > 4 sites. A 2011 review of EMB from
Mayo Clinic found the complication rates to be less than 6%

Teaching point
Amyloidosis can present with neuropathic symptoms in
addition to cardiomyopathy. Genetic analysis is integral in
defining treatment options for FAP.
Table 1  Differential diagnosis
of increased left ventricular wall
thickness
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Hypertrophic cardiomyopathy
Hypertensive heart disease
Fabry’s disease
Amyloidosis
Athlete heart
Glycogen storage diseases

Fig. 4  Apical 4-chamber view showing severe left and right ventricular hypertrophy as well as granular sparkling appearance in patient 1
with wtATTR but s initially suspected as having HCM
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Fig. 5  Restrictive mitral flow pattern, right upper pulmonary vein pulse Doppler showing systolic blunting consistent with restrictive inflow, tissue Doppler imaging of the medial and lateral mitral annulus with very low systolic, and e’ velocities in patient 1 with wtATTR

in most case series. Reported complications include access
site hematoma, transient right bundle branch block, transient
arrhythmias, tricuspid regurgitation, and occult pulmonary
embolism. Right ventricular perforation was reported in less
than 1% of patients in recent reports [7]. As mentioned in
above, patient 1 developed a complete heart block during his
EMB which required atropine and dopamine. Thus, EMB
should ideally be reserved as the final step when comprehensive laboratory and imaging workup still remain inconclusive. Extra-cardiac sites for biopsy diagnosis have met
with variable success. In a large study of 286 ATTR-CA
patients by Fine and colleagues, non-cardiac organ biopsy or
fat aspiration was positive nearly ¾ of the time. Overall, 210
patients had positive results on non-cardiac sampling. Nearly
all patients (n-175/186, 94%) with mtATTR had positive
histologic findings on non-cardiac tissue sampling (either
fat aspiration or bone marrow biopsy), whereas only 35%
(35/100) of the patients with wtATTR had positive results
[8]. Endomyocardial biopsy which was performed in 46%
of study population was 100% positive. Hence, although

not unreasonable to consider extra-cardiac tissue sampling,
it is important to be aware that the positivity rate, particularly for wtATTR amyloidosis, can be fairly low. Patient 1
with wtATTR-CA had a negative fat pad biopsy and patient
3 with mtATTR-CA (T60A mutation) had positive fat pad
biopsy reiterating above study findings.
Given the challenges of biopsy, the current diagnostic
approach for CA involves multimodality imaging in conjunction with assessment of a plasma-cell dyscrasia. Serum and
urine immunofixation and the measurement of serum free
light chains (FLCs) are necessary for the diagnosis of AL
amyloidosis. The sensitivity of serum plasma electrophoresis for AL amyloidosis is ~ 70%, whereas the sensitivity of
serum IFE is > 90% [9]. Together, measurement of serum
IFE, urine IFE, and serum free light chain is > 99% sensitive
for AL amyloidosis [10, 11]. This is key as missing a diagnosis of AL amyloidosis can be disastrous for patients given
the high mortality and only depending on imaging may result
in unacceptable false positive rates for ATTR amyloidosis.
In the cases illustrated, patients 1 and 3 had AL excluded
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Fig. 6  Classic example of reduced global longitudinal strain with apical sparing aka “cherry on top” in a patient with wtATTR-CA. GLS
was − 7%

by normal SPEP, UPEP, immunofixation, and monoclonal
protein screening. Patient 2’s workup for light chains was
abnormal. He underwent hematological evaluation as well
as bone marrow biopsy and was found to have coexisting
MGUS with concomitant multimodality imaging confirming ATTR-CA.

Role of multimodality imaging

Fig. 7  Apical 4-chamber view showing biventricular increased wall
thickness, thickening of mitral and tricuspid valve, and atrial enlargement. Speckle-tracking LV strain assessment bullseye image with dif-

fuse reduction in strain but with relative apical sparing global longitudinal strain in patient 3 with T60A positive hATTR, with a mixed
neuropathic and cardiomyopathic form of amyloidosis

13

The use of multimodality cardiac imaging either directly
identifies the presence of amyloid fibrils or indirectly images
the effects of that infiltration on the myocardium: increased
tissue calcium, interstitial expansion, and inflammation and

Heart Failure Reviews
Fig. 8  Normal left atrial strain
and abnormal left atrial strain in
a patient with known wtATTR
showing the markedly reduced
left atrial reservoir strain

edema. In order for multimodality imaging to be cost effective, the initial clinical suspicion of CA should be correlated
with the patient’s presentation of heart failure, arrhythmias,
and/or systemic autonomic and neurological symptoms as
well as electrocardiography (ECG) and echocardiography (as
discussed in clinical clues table of epidemiology section).

Electrocardiography and echocardiography
The presence of low voltage on ECG is a well-known and
sought after finding in the diagnosis of CA. However, the
absence of low voltage should not be used to exclude CA
as in Fig. 1. Although AL-CA can cause low voltage in up
to 60% of cases, low voltage EKG in ATTR-CA is highly
variable and seen in only 20% with mtATTR and up to 40%
wild type ATTR-CA [12]. Bundle branch block and voltage
criteria for LVH may in fact be seen in patients with CA
as noted in patient 1, Fig. 2 [13]. Patients 2 and 3 both had
normal precordial voltage. The ECG for patient 3 showed
inferior Q waves with no coronary artery disease (pseudoinfarct pattern), Fig. 3. Thus, ECG can sometimes provide

clues, but additional imaging plays a key role in solidifying
suspicion for CA.
Echocardiography (echo) is often the initial imaging
study in evaluating patients suspected of CA due to ease,
availability, portability, and ability to identify morphological and pathological consequences of amyloid deposition.
The presence of left ventricle wall thickness > 1.2 cm [14]
particularly in patients with controlled hypertension and
heart failure with preserved ejection fraction should raise
Table 2  Key echo findings in cardiac amyloidosis
Increased left ventricular thickness
Speckled appearance of myocardium
Thickened valves
Thickened atrial septum
Pericardial effusions
Atrial dilation
Diastolic dysfunction
Abnormal global strain
Apical sparing pattern on strain
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Fig. 9  CMR composite with increased myocardial wall thickening as well as 3-chamber post-contrast image showing extensive LV enhancement
as well as left atrial LGE in a patient with wtATTR

the differential of CA amongst other causes (Table 1).
The suspicion is strengthened by the discordance between
ECG voltage and wall thickness and the echo LV mass/
ECG voltage ratio has been shown to carry more diagnostic value than ECG voltage alone [15]. As illustrated
in patient case 1, ATTR-CA can mimic HCM, Fig. 4. The
initial echo for this patient showed massive asymmetric
septal hypertrophy and increased LV and RV wall thickness and was initially treated as non-obstructive HCM.

Asymmetric septal hypertrophy and reversed septal curvature mimicking HCM can be seen in up to 70% and
30% of CA patients, respectively [16]. Intraventricular
dynamic obstructive physiology mimicking HCM can
also be seen [17]. A granular sparkling appearance of the
myocardial walls may be appreciated as in patient case 1
(Fig. 4), but it is not considered highly specific and has
been reported in hypertensive as well as end-stage renal
disease patients [18].

Fig. 10  CMR composite showing extensive LV wall thickness and diffuse biatrial and biventricular delayed myocardial enhancement in patient 3
with mtATTR
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Fig. 11  Post-gadolinium 4-chamber and short-axis images in patient 2 with MGUS and wtATTR showing diffuse myocardial LV enhancement
and RV enhancement

Tissue Doppler imaging (TDI) and speckle-tracking echocardiography permit a non-invasive evaluation of this pathological change secondary to infiltration of amyloid fibrils. TDI
will show reduced myocardial systolic (S’) and diastolic (e’)
and longitudinal velocities as shown for patient 1 in Fig. 5.
The degree of TDI dysfunction is usually worse in CA than
HCM [19]. Reduced longitudinal shortening with preserved
LV ejection fraction (due to preserved radial shortening) is
seen in earlier phases of CA although stroke volume may be

low. Both AL- and ATTR-CA patients demonstrate a typical pattern of distribution of speckle-tracking echo-derived
global longitudinal strain (GLS) in which basal LV segments
are severely impaired while apical segments are relatively
spared popularly referred to as “apical sparing” or cherry on
top appearance [20, 21] as seen in the echos of patients 2
and 3, Figs. 6 and 7. However, an important caveat in using
echocardiographic strain imaging is that “apical sparing”
pattern is not specific for CA as this pattern has also been

Fig. 12  Native T1 maps of short-axis and 4-chamber slices before
gadolinium administration (1.5 T), in patient 2 with confirmed
MGUS and wtATTR. The native septal T1 was 1115 ms, while the

septal post-contrast T1 was 340 ms, resulting in a markedly elevated
ECV of 54.7% (normal 23–29%)
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reported in hypertensive heart disease and end-stage renal disease [22]. Hence, in the right clinical setting, echo findings
can definitely raise the suspicion for CA which then requires
confirmation with laboratory testing, bone marrow biopsy,
advanced cardiac imaging, and if needed EMB. The ratio
of LVEF to global longitudinal strain (EF/GLS) can also be
used to differentiate amyloidosis from other forms of cardiac
hypertrophy with preserved ejection fraction and a ratio of
EF/GLS > 4 was the most accurate predictor of CA, performing better than other traditional deformation parameters especially in challenging cases of CA with only mild increased
LV wall thickness [23]. The degree of reduction in GLS has
been shown to correlate with MRI fibrosis and the lower
the GLS correlateing with lower EF. Left atrial strain by
Fig. 13  A and B H/CL (heart/
contralateral lung) lung-ratio
methodology with measurement
of mean counts per pixel for
target (heart) and background
(contralateral chest) ratio at 1 h
(> 1.5 suggestive of ATTR-CA).
SPECT images confirm diffuse
pyrophosphate radio-tracer
uptake in the myocardium, differentiating myocardial uptake
from blood pool or overlying
bone uptake
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speckle-tracking echocardiography is another emerging echocardiographic tool to further delineate cardiac dysfunction and
extent of CA infiltration. Figure 8 shows marked atrial dysfunction in a patient with advanced CA compared to a normal
atrial strain pattern in a control.
The key echocardiographic findings of CA are summarized in Table 2 [12, 20, 24–26].

CMR
While echocardiography is often the initial test in evaluation of CA, the ability of CMR to provide tissue characterization in addition to high-resolution morphologic and functional assessment makes CMR an excellent modality after
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abnormal echo or to evaluate patients with systemic amyloidosis for early manifestations of cardiac amyloid. More
importantly when evaluating for different causes of cardiomyopathy, CMR offers unparalleled morphologic and
tissue characterization information. CMR for amyloidosis includes cine imaging, evaluation of native T1 signal
(assessed on non-contrast T1 mapping prior to gadolinium infusion), assessment of late gadolinium enhancement using phase sensitive inversion recovery (PSIR), and
extracellular volume (ECV) measurement. Gadolinium is
a purely extracellular agent, and thus in CA, its volume
of distribution is proportional to the interstitial expansion
secondary to amyloid deposition [27]. Early CMR studies in cardiac amyloidosis described altered gadolinium
kinetics, difficulty nulling the myocardium, and a global
subendocardial pattern of late gadolinium enhancement
(LGE) [28].
Multiple LGE distributions have been described in both
ATTR- and AL-CA and studies have shown the extent of
LGE in MRI has implications for adverse outcomes in CA.
In a prospective study by Fontana et al., 250 patients (119
with AL, 122 with ATTR, and 9 asymptomatic mutation
carriers) were studied with MRI with and without PSIR for
LGE imaging. PSIR-based LGE assessment was superior
and the patterns of LGE from none, to subendocardial, and

finally to transmural enhancement were correlated with progressive increase in ECV. Overall, this study showed that
a pattern of transmural enhancement was an independent
predictor of adverse outcomes [29]. This differs from the
pattern of LGE seen in HCM. LGE in HCM is often heterogeneous and patchy throughout the areas of hypertrophy and
along the superior and inferior RV insertion sites [30, 31].
Both patients 1 and 3 were initially suspected of having
HCM secondary to increased LV wall thickness, CMR was
crucial in clarifying the etiology of hypertrophy, and given
the extent of LGE, an infiltrative process such as amyloidosis
was added to the differential by CMR, Figs. 9 and 10. Patient
2 with wtATTR in the setting of MGUS also had extensive LGE and inability to null the myocardium on his CMR,
Fig. 11. In addition to LGE of the ventricular myocardium,
delayed enhancement of the atrial wall is a strong clue to
the presence of CA [32]. Patient 1 had LGE enhancement
of his left atria, which further helped delineate the diagnosis
of CA versus HCM, Fig. 9. CMR patterns of LGE serve as
a valuable adjunct to echo to clarify cardiomyopathy etiology, but cannot conclusively distinguish ATTR from AL
amyloidosis.
Newer parametric CMR techniques are making it into the
mainstream clinical arena, which further adds to the ability of CMR to differentiate tissue characteristics. Native T1

Fig. 14  A and B PYP-SPECT confirming diffuse radio-tracer uptake in the myocardium. Planar imaging at 3 h with H/CL ratio of 1.6 (> 1.3
abnormal)
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Fig. 15  A and B PYP planar chest views 1 h after injection with grade 3 uptake. 99mTc PYP myocardial uptake is greater than rib uptake with
mild/absent rib uptake. SPECT images confirm diffuse increased cardiac uptake
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Fig. 16  Henry Ford Cardiac Amyloidosis Clinic Algorithm. Adapted and modified from references in figure. Note: Patients get monoclonal
screen completed prior to PYP-SPECT being done
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mapping performed pre-gad and post-gad T1 maps allow a
quantitative measure of ECV, which is significantly elevated
in CA. Furthermore, ECV is elevated even when conventional testing and gadolinium-enhanced imaging techniques
suggest no cardiac involvement. Therefore, ECV measurements may be helpful in early disease as well as to track
progression and even treatment as ECV parallels amyloid
burden [33, 34]. Significantly, prolonged T1 time is a characteristic of CA [35] and post-contrast shortening of T1 time
is also seen with CA [34, 36]. Furthermore, T1 is elevated
in ATTR patients compared with HCM and normal subjects [36]. T1 pre- and post-contrast maps and calculations
of ECV are included for patient 2, Fig. 12. An advantage of
native T1 mapping is that it does not require gadolinium.
Therefore, if certain CMR morphologic features suggest CA,
pre-contrast T1 time may further support that diagnosis in
patients where gadolinium administration may not be suitable such as those with advanced chronic kidney disease.

Technetium‑99 m pyrophosphate nuclear
cardiac scintigraphy
There is a unique myocardial uptake pattern in CA
with nuclear scintigraphy using 99mTechnetium (Tc)bisphosphonate derivatives such as 99mTc-pyrophosphate
(PYP) available in USA), as well as 99mTc-3,3diphosphono-1,2-propanodicarboxylicacid (99mTcDPD) and 99mTc hydroxymethylenediphosphonate (99mTcHMDP) which are both used in other parts of the world
and not available in USA. The mechanism underlying the
myocardial retention of these tracers is unknown but has
been attributed to the presence of microcalcifications that
are more common in ATTR than AL cardiac tissue [37].
Therefore, radionuclide imaging provides critical information on amyloid type that is not available by echo or CMR.
PYP imaging has brought the reality “non-biopsy diagnosis”
of CA to fruition. A seminal study involving a large cohort
of endomyocardial biopsy-proven cases of ATTR-CM concluded that these bone avid tracers conferred 100% specificity for ATTR-CM when grade 2 or 3 uptake of PYP was seen
in the absence of a monoclonal protein by serum and urine
testing in patients with HF and typical echocardiographic
or CMR findings of amyloidosis [38]. PYP scanning is also
capable of identifying the presence of cardiac amyloidosis
prior to LGE on CMR.
The diagnostic parameters of PYP scan have traditionally
included the ratio heart-to-contralateral (H/CL) lung uptake
(semiquantitative scoring), the Perugini grading system
of heart-to-bone uptake (visual grade) based on uptake in
the heart on planar at both 1 and 3 h. However, increasingly false positive cases and overdiagnosis of CA based on
planar imaging due to blood pool accumulation of isotope
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have brought to light the importance of SPECT-CT in the
confirmation of diffuse myocardial uptake, now considered
an integral finding to confirm ATTR-CA to avoid misdiagnosis [18]. Single-photon emission computed tomography
(SPECT) should be assessed in all positive scans to confirm
that uptake actually represents myocardial retention of the
tracer, not simply blood pool signal [39]. The visual assessment of SPECT-CT uptake is now the preferred approach to
PYP to confirm CA.
Patient 1 demonstrated heart/contralateral lung ratio of
2.4 as well as visual grade 3 myocardial uptake on PYP as
well as diffuse uptake of PYP on SPECT, Fig. 13. Patient
2 had a 3-h PYP study. The H/CL for patient 2 was 1.6 at
3 h, Fig. 14. The SPECT-CT images also indicated grade
3 uptake with activity significantly over adjacent rib bony
uptake confirming ATTR-CA, Fig. 14. The planar and
SPECT images for patient 3 show grade 3 Perugini grading
as well as diffuse myocardial uptake and not pooling of the
radionuclide tracer within the blood pool, Fig. 15.

Summary
The 3 cases above and accompanying discussion on multimodality imaging illustrate the complementary roles of
multimodality imaging in CA. As discussed, a systematic
approach with suspicion for the clinical clues, EKG and
echo features, and use of advanced cardiac imaging with
CMR and PYP imaging along with genetic analysis helps
to solidify a non-biopsy diagnosis of CA. However, despite
use of imaging, there may be some cases which fall in the
“grey zone” and these require conclusive evaluation with
EMB which is the preferred tissue approach for diagnosis.
We present an algorithm of our systematic approach adapted
and modified from existing data that we use in practice to
integrate all tools to arrive at the diagnosis of cardiac amyloidosis, Fig. 16.
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